Amgen Ovarian Cancer Drug Meets Goal of Late-Stage Study

Amgen Inc., the world’s largest biotechnology company by sales, said its experimental drug for recurrent ovarian cancer met a late-stage study goal, helping patients live 1.8 months longer without the disease progressing.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.